Tandem Diabetes Care (TNDM) Financials

$21.28 +0.13 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$21.30 +0.02 (+0.09%)

As of 07:57 PM Eastern

Annual Income Statements for Tandem Diabetes Care

This table shows Tandem Diabetes Care's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-99	-219	-96	15	-34	-25	-123	-73	-83	-72	-80
Consolidated Net Income / (Loss)	-96	-223	-95	16	-34	-25	-123	-73	-83	-72	-80
Net Income / (Loss) Continuing Operations	-96	-223	-95	16	-34	-25	-123	-73	-83	-72	-80
Total Pre-Tax Income	-92	-220	-93	16	-36	-25	-123	-73	-83	-72	-79
Total Operating Income	-99	-233	-93	23	-7.96	-17	-45	-63	-78	-69	-76
Total Gross Profit	490	368	413	376	261	194	90	44	24	27	15
Total Revenue	940	748	801	703	499	362	184	108	84	73	50
Operating Revenue	940	748	801	703	499	362	184	108	84	73	50
Total Cost of Revenue	451	380	388	327	238	168	94	64	61	46	34
Operating Cost of Revenue	451	380	388	327	238	168	94	64	61	46	34
Total Operating Expenses	589	601	506	354	268	211	134	107	102	96	91
Selling, General & Admin Expense	390	353	336	262	205	166	105	86	83	79	75
Research & Development Expense	199	248	170	92	64	45	29	21	19	17	16
Total Other Income / (Expense), net	7.26	13	-0.00	-6.75	-28	-7.88	-78	-10	-5.41	-3.40	-3.79
Interest Expense	8.68	9.88	6.21	6.04	13	0.00	13	11	5.71	3.74	3.90
Interest & Investment Income	16	23	6.06	0.67	1.57	3.19	1.44	0.24	0.30	0.34	0.11
Other Income / (Expense), net	0.00	0.00	0.15	-1.39	-17	-11	-66	1.02	-	-	-
Income Tax Expense	4.16	2.36	1.74	0.34	-1.90	0.15	0.05	0.01	-0.02	0.01	0.07
Basic Earnings per Share	($1.47)	($3.43)	($1.47)	$0.25	($0.56)	($0.42)	($2.55)	($12.87)	($27.30)	($25.04)	($3.42)
Weighted Average Basic Shares Outstanding	65.45M	64.97M	64.15M	63M	60.99M	58.51M	48.13M	5.68M	3.06M	2.89M	23.27M
Diluted Earnings per Share	($1.47)	($3.43)	($1.47)	$0.24	($0.56)	($0.42)	($2.55)	($12.87)	($27.30)	($25.04)	($3.42)
Weighted Average Diluted Shares Outstanding	65.45M	64.97M	64.15M	64.35M	60.99M	58.51M	48.13M	5.68M	3.06M	2.89M	23.27M
Weighted Average Basic & Diluted Shares Outstanding	66.47M	65.63M	64.53M	63.87M	60.99M	58.51M	48.13M	5.68M	3.06M	2.89M	23.27M

This table shows Tandem Diabetes Care's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-129	0.06	-23	-31	-45	-26	-34	-37	-122	-15	-50
Consolidated Net Income / (Loss)	-131	0.76	-23	-31	-43	-30	-33	-36	-124	-16	-49
Net Income / (Loss) Continuing Operations	-131	0.76	-23	-31	-43	-30	-33	-36	-124	-16	-49
Total Pre-Tax Income	-122	0.02	-23	-30	-40	-31	-31	-35	-124	-16	-47
Total Operating Income	-121	-0.58	-26	-31	-42	-35	-32	-39	-128	-18	-47
Total Gross Profit	118	157	125	113	95	93	90	102	83	116	104
Total Revenue	234	283	244	222	192	197	186	196	169	221	205
Operating Revenue	234	283	244	222	192	197	186	196	169	221	205
Total Cost of Revenue	116	125	119	109	97	104	96	94	86	105	100
Operating Cost of Revenue	116	125	119	109	97	104	96	94	86	105	100
Total Operating Expenses	239	158	151	144	136	128	121	141	211	133	152
Selling, General & Admin Expense	114	106	100	94	90	86	79	98	90	98	84
Research & Development Expense	125	52	51	49	46	43	42	43	121	36	68
Total Other Income / (Expense), net	-1.21	0.60	3.48	1.03	2.15	3.75	0.82	4.18	4.23	1.66	0.14
Interest Expense	1.86	1.86	1.87	1.79	3.17	1.80	4.84	1.61	1.63	1.58	1.58
Interest & Investment Income	0.65	2.46	5.34	2.82	5.31	5.55	5.66	5.78	5.87	3.10	1.72
Income Tax Expense	8.47	-0.74	0.64	1.07	3.19	-1.31	2.23	1.15	0.29	-0.26	1.62
Basic Earnings per Share	($1.97)	-	($0.35)	($0.47)	($0.65)	($0.45)	($0.51)	($0.55)	($1.92)	($0.25)	($0.76)
Weighted Average Basic Shares Outstanding	66.40M	65.45M	65.54M	64.99M	65.33M	64.97M	65.12M	64.83M	64.55M	64.15M	64.24M
Diluted Earnings per Share	($1.97)	-	($0.35)	($0.47)	($0.65)	($0.45)	($0.51)	($0.55)	($1.92)	($0.24)	($0.76)
Weighted Average Diluted Shares Outstanding	66.40M	65.45M	65.54M	64.99M	65.33M	64.97M	65.12M	64.83M	64.55M	64.15M	64.24M
Weighted Average Basic & Diluted Shares Outstanding	66.61M	66.47M	65.68M	65.46M	64.59M	65.63M	65.21M	65.08M	64.62M	64.53M	64.30M

This table details how cash moves in and out of Tandem Diabetes Care's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	10	-114	101	-23	43	9.35	18	-23	1.59	12	-93
Net Cash From Operating Activities	24	-32	50	111	25	42	-8.32	-66	-61	-59	-61
Net Cash From Continuing Operating Activities	24	-32	50	111	25	42	-8.32	-66	-61	-59	-61
Net Income / (Loss) Continuing Operations	-96	-223	-95	16	-34	-25	-123	-73	-83	-72	-80
Consolidated Net Income / (Loss)	-96	-223	-95	16	-34	-25	-123	-73	-83	-72	-80
Depreciation Expense	17	16	14	14	10	6.07	5.82	6.87	5.49	4.83	4.39
Amortization Expense	-0.23	5.79	6.08	2.09	8.80	-0.57	2.26	1.87	0.19	0.14	0.17
Non-Cash Adjustments To Reconcile Net Income	117	186	128	63	79	78	98	14	17	14	15
Changes in Operating Assets and Liabilities, net	-13	-17	-3.66	17	-39	-17	8.61	-16	0.03	-5.04	-1.76
Net Cash From Investing Activities	-23	-86	33	-187	-296	-57	-91	2.78	10	2.42	-35
Net Cash From Continuing Investing Activities	-23	-86	33	-187	-296	-57	-91	2.78	10	2.42	-35
Purchase of Property, Plant & Equipment	-19	-27	-34	-14	-27	-20	-2.99	-5.72	-8.93	-5.76	-4.41
Acquisitions	0.00	-69	-26	0.00	0.00	-	0.00	-	-	-0.07	-0.17
Purchase of Investments	-264	-511	-468	-733	-502	-165	-124	0.00	-31	-80	-67
Sale and/or Maturity of Investments	306	546	569	570	233	127	36	8.50	50	88	36
Other Investing Activities, net	-46	-25	-8.86	-9.33	-	-	-	-	-	-	-
Net Cash From Financing Activities	8.37	4.11	17	52	314	24	117	40	52	68	3.64
Net Cash From Continuing Financing Activities	8.37	4.11	17	52	314	24	117	40	52	68	3.64
Repayment of Debt	-246	-0.07	-0.59	0.00	0.00	-	-88	0.00	-	-	-30
Repurchase of Common Equity	-30	0.00	0.00	-	-	-	-	-	-	-	-
Issuance of Debt	307	0.00	0.00	-	279	0.00	0.00	-	50	-	30
Issuance of Common Equity	-6.73	4.18	17	51	67	24	2.39	40	2.32	3.39	3.66
Other Financing Activities, net	-16	0.00	0.00	0.59	-31	0.33	203	0.00	-	65	0.05
Effect of Exchange Rate Changes	1.26	-0.21	0.83	0.15	0.39	0.19	-	-	-	-	-
Cash Interest Paid	3.08	7.57	4.31	4.31	2.71	0.00	11	7.88	4.40	3.35	3.37
Cash Income Taxes Paid	3.10	1.92	0.41	0.26	0.18	0.07	0.02	0.02	0.02	0.01	0.07

This table details how cash moves in and out of Tandem Diabetes Care's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-16	20	1.34	-11	0.11	-21	-51	2.99	-45	49	8.82
Net Cash From Operating Activities	-18	11	27	-5.28	-8.00	-7.22	0.06	-6.32	-18	5.82	24
Net Cash From Continuing Operating Activities	-18	11	27	-5.28	-8.00	-7.22	0.06	-6.32	-18	5.82	24
Net Income / (Loss) Continuing Operations	-131	0.76	-23	-31	-43	-30	-33	-36	-124	-16	-49
Consolidated Net Income / (Loss)	-131	0.76	-23	-31	-43	-30	-33	-36	-124	-16	-49
Depreciation Expense	4.31	4.25	4.21	4.11	4.04	4.03	4.02	4.27	3.40	3.64	3.51
Amortization Expense	-0.64	-1.22	-0.44	1.22	0.22	0.90	2.12	1.95	0.82	1.31	2.08
Non-Cash Adjustments To Reconcile Net Income	112	33	30	28	26	24	22	39	101	33	54
Changes in Operating Assets and Liabilities, net	-3.77	-26	16	-8.21	4.96	-6.36	4.82	-16	0.01	-16	13
Net Cash From Investing Activities	9.19	5.01	-20	-3.54	-5.06	-17	-49	5.70	-26	36	-14
Net Cash From Continuing Investing Activities	9.19	5.01	-20	-3.54	-5.06	-17	-49	5.70	-26	36	-14
Purchase of Property, Plant & Equipment	-2.97	-3.07	-5.24	-6.47	-4.46	-5.20	-5.40	-7.38	-8.83	-5.63	-14
Acquisitions	-43	-	-	-	0.00	-	-	-	-69	-0.02	-26
Purchase of Investments	-9.45	-13	-74	-93	-84	-120	-156	-126	-109	-105	-132
Sale and/or Maturity of Investments	65	67	59	96	84	131	112	140	163	147	166
Net Cash From Financing Activities	-4.69	2.30	-4.52	-3.00	14	2.62	-1.91	3.95	-0.54	6.10	-0.77
Net Cash From Continuing Financing Activities	-4.69	2.30	-4.52	-3.00	14	2.62	-1.91	3.95	-0.54	6.10	-0.77
Repayment of Debt	0.00	-	-	-	-246	-	-0.07	-	0.00	0.08	-0.41
Repurchase of Common Equity	0.00	-	-	-	-30	-	-	-	0.00	-	-
Issuance of Debt	0.00	-	-	-	307	-	-	-	0.00	-	-
Other Financing Activities, net	-4.69	-	-	-	-16	-	-	-	0.00	-0.08	-
Effect of Exchange Rate Changes	-1.88	2.17	-1.02	0.54	-0.42	0.44	-0.76	-0.33	0.44	1.03	-0.19
Cash Income Taxes Paid	1.56	1.80	0.12	0.91	0.27	0.15	-	1.40	0.37	0.25	-

This table presents Tandem Diabetes Care's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	968	953	1,053	905	716	326	206	95	112	125	106
Total Current Assets	724	748	850	812	637	276	188	64	92	107	91
Cash & Equivalents	69	59	173	71	95	51	42	14	45	43	31
Short-Term Investments	369	409	444	553	390	125	87	0.48	8.86	28	36
Accounts Receivable	115	106	115	111	82	47	35	21	11	14	7.65
Inventories, net	150	158	111	69	64	49	20	27	21	18	12
Prepaid Expenses	22	17	7.24	8.43	6.38	4.03	3.77	2.19	4.19	2.28	1.90
Plant, Property, & Equipment, net	78	77	69	50	50	33	17	20	18	16	13
Total Noncurrent Assets	165	128	134	43	29	17	1.26	12	1.89	2.22	3.13
Long-Term Investments	75	0.00	-	-	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	90	128	134	43	29	17	1.26	0.10	0.11	0.11	0.69
Total Liabilities & Shareholders' Equity	968	953	1,053	905	716	326	206	95	112	125	106
Total Liabilities	705	639	613	472	350	131	75	124	118	61	52
Total Current Liabilities	247	195	165	132	104	99	66	36	31	27	18
Short-Term Debt	41	0.00	-	-	-	-	-	-	-	-	-
Accounts Payable	45	50	56	28	18	18	6.82	5.15	7.51	5.23	1.95
Accrued Expenses	18	13	9.60	9.42	4.78	8.01	3.93	2.83	1.63	2.12	2.92
Current Deferred Revenue	12	44	19	10	6.08	3.87	4.60	2.53	5.21	1.82	0.84
Current Employee Benefit Liabilities	64	43	39	52	34	28	24	14	10	12	9.72
Other Current Liabilities	68	46	42	33	41	41	27	11	6.94	5.58	2.66
Total Noncurrent Liabilities	458	444	448	340	246	32	8.73	88	87	35	34
Long-Term Debt	308	285	283	281	203	0.00	-	77	79	29	29
Noncurrent Deferred Revenue	10	13	17	17	-	-	-	4.69	2.61	2.74	2.70
Other Noncurrent Operating Liabilities	139	145	147	42	43	32	8.73	7.18	5.27	2.72	1.66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	263	314	440	433	366	195	131	-29	-5.93	63	55
Total Preferred & Common Equity	263	314	440	433	366	195	131	-29	-5.93	63	55
Total Common Equity	263	314	440	433	366	195	131	-29	-5.93	63	55
Common Stock	1,313	1,264	1,171	1,068	1,025	820	731	448	399	385	303
Retained Earnings	-1,048	-952	-729	-635	-659	-625	-600	-478	-405	-321	-249
Accumulated Other Comprehensive Income / (Loss)	-1.95	1.37	-1.82	-0.62	0.22	0.12	-0.01	-	-0.00	0.02	0.01

This table presents Tandem Diabetes Care's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	922	958	938	941	940	947	954	1,048
Total Current Assets	663	753	733	735	758	764	758	834
Cash & Equivalents	54	49	48	59	80	131	128	124
Short-Term Investments	315	424	405	409	419	376	392	485
Accounts Receivable	127	107	98	93	100	99	91	113
Inventories, net	141	152	162	154	143	148	132	105
Prepaid Expenses	27	20	21	21	16	11	15	8.00
Plant, Property, & Equipment, net	79	81	79	78	76	74	75	73
Total Noncurrent Assets	179	124	125	128	106	109	122	140
Long-Term Investments	71	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	108	124	125	128	106	109	122	140
Total Liabilities & Shareholders' Equity	922	958	938	941	940	947	954	1,048
Total Liabilities	767	720	704	698	626	617	615	626
Total Current Liabilities	288	259	241	193	187	175	171	174
Short-Term Debt	41	41	41	-	-	-	-	-
Accounts Payable	60	49	48	48	46	57	55	62
Accrued Expenses	14	12	13	11	14	13	10	7.90
Current Deferred Revenue	11	43	44	45	32	23	21	13
Current Employee Benefit Liabilities	50	59	43	42	44	35	39	48
Other Current Liabilities	113	56	52	48	52	46	46	43
Total Noncurrent Liabilities	479	461	463	505	439	443	444	452
Long-Term Debt	309	308	307	347	285	284	284	283
Noncurrent Deferred Revenue	9.86	11	12	12	14	15	16	19
Other Noncurrent Operating Liabilities	160	142	144	145	140	143	145	150
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	155	238	234	243	314	329	339	422
Total Preferred & Common Equity	155	238	234	243	314	329	339	422
Total Common Equity	155	238	234	243	314	329	339	422
Common Stock	1,334	1,282	1,260	1,239	1,238	1,219	1,192	1,140
Retained Earnings	-1,178	-1,049	-1,025	-995	-922	-889	-853	-713
Accumulated Other Comprehensive Income / (Loss)	0.08	3.87	-1.25	-0.94	-2.21	-1.19	-0.09	-5.06

This table displays calculated financial ratios and metrics derived from Tandem Diabetes Care's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.74%	-6.68%	14.00%	40.89%	37.68%	97.05%	70.88%	27.72%	15.65%	46.51%	71.41%
EBITDA Growth	60.92%	-192.89%	-294.30%	742.22%	74.01%	78.37%	-93.73%	26.51%	-13.02%	9.95%	-30.06%
EBIT Growth	57.50%	-151.59%	-535.89%	184.92%	9.90%	74.99%	-79.46%	20.66%	-13.11%	8.80%	-29.48%
NOPAT Growth	57.50%	-151.20%	-393.08%	498.14%	52.42%	62.53%	29.09%	19.36%	-13.11%	8.80%	-53.06%
Net Income Growth	56.86%	-135.33%	-707.70%	145.27%	-38.90%	79.81%	-67.88%	12.48%	-15.23%	8.94%	-25.95%
EPS Growth	57.14%	-133.33%	-712.50%	142.86%	-33.33%	83.53%	80.19%	52.86%	-15.23%	8.94%	84.06%
Operating Cash Flow Growth	176.16%	-163.04%	-54.68%	351.41%	-41.13%	603.74%	87.42%	-8.11%	-4.10%	4.26%	-28.52%
Free Cash Flow Firm Growth	79.87%	-133.20%	-610.79%	122.07%	-155.20%	-172.28%	79.36%	5.17%	1.35%	1.99%	-13.09%
Invested Capital Growth	-24.16%	23.03%	17.09%	7.60%	355.45%	723.89%	-90.32%	32.69%	-10.91%	33.31%	9.89%
Revenue Q/Q Growth	10.05%	-3.07%	1.33%	6.34%	13.59%	9.75%	24.27%	11.83%	-0.25%	18.23%	18.16%
EBITDA Q/Q Growth	28.24%	-8.90%	-70.23%	-24.10%	81.56%	-4.87%	-127.76%	10.03%	-2.66%	8.86%	-1.21%
EBIT Q/Q Growth	25.81%	-8.00%	-48.72%	-29.21%	43.86%	-4.47%	-102.88%	7.17%	-2.80%	8.34%	-1.39%
NOPAT Q/Q Growth	25.81%	-8.00%	-48.96%	-22.27%	67.49%	8.65%	18.52%	5.64%	-2.80%	8.34%	-1.39%
Net Income Q/Q Growth	24.26%	-6.79%	-39.25%	-28.46%	29.44%	-4.36%	10.96%	4.47%	-3.38%	8.09%	6.08%
EPS Q/Q Growth	23.44%	-6.52%	-38.68%	-33.33%	30.00%	-5.00%	-2.82%	12.63%	-3.38%	8.09%	-102.10%
Operating Cash Flow Q/Q Growth	285.01%	-69.44%	-21.49%	4.11%	-14.57%	14.51%	75.60%	2.85%	-5.77%	5.30%	-1.17%
Free Cash Flow Firm Q/Q Growth	64.33%	-20.57%	-26.14%	12.75%	-4.65%	-33.15%	31.90%	14.17%	-5.06%	2.65%	0.00%
Invested Capital Q/Q Growth	-12.12%	30.21%	10.84%	19.92%	37.96%	84.34%	21.65%	-7.51%	26.78%	15.63%	-1.94%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.07%	49.18%	51.54%	53.53%	52.23%	53.60%	48.85%	40.98%	28.00%	36.49%	30.67%
EBITDA Margin	-8.80%	-28.32%	-9.02%	5.29%	-1.16%	-6.15%	-56.04%	-49.43%	-85.90%	-87.90%	-143.01%
Operating Margin	-10.54%	-31.19%	-11.59%	3.22%	-1.60%	-4.62%	-24.27%	-58.50%	-92.64%	-94.72%	-152.17%
EBIT Margin	-10.54%	-31.19%	-11.57%	3.03%	-5.02%	-7.67%	-60.44%	-57.55%	-92.64%	-94.72%	-152.17%
Profit (Net Income) Margin	-10.21%	-29.77%	-11.81%	2.21%	-6.89%	-6.83%	-66.69%	-67.87%	-99.05%	-99.41%	-159.94%
Tax Burden Percent	104.52%	101.07%	101.88%	97.89%	94.76%	100.61%	100.04%	100.01%	99.98%	100.01%	100.09%
Interest Burden Percent	92.68%	94.44%	100.16%	74.77%	144.87%	88.51%	110.29%	117.93%	106.93%	104.93%	105.01%
Effective Tax Rate	0.00%	0.00%	0.00%	2.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-60.36%	-137.75%	-65.97%	25.33%	-10.83%	-112.72%	-245.40%	-216.47%	-294.28%	-281.10%	-376.52%
ROIC Less NNEP Spread (ROIC-NNEP)	-45.00%	-114.77%	-57.21%	27.44%	1.74%	-104.18%	-7.04%	-292.93%	-11.94%	-223.46%	-339.10%
Return on Net Nonoperating Assets (RNNOA)	27.06%	78.67%	44.30%	-21.43%	-1.42%	97.55%	5.28%	632.91%	4.23%	158.40%	283.02%
Return on Equity (ROE)	-33.30%	-59.08%	-21.67%	3.89%	-12.25%	-15.17%	-240.11%	416.44%	-290.04%	-122.70%	-93.50%
Cash Return on Invested Capital (CROIC)	-32.88%	-158.41%	-81.71%	18.00%	-138.81%	-269.42%	-80.71%	-244.56%	-282.74%	-309.66%	-385.94%
Operating Return on Assets (OROA)	-10.32%	-23.26%	-9.47%	2.62%	-4.80%	-10.44%	-73.68%	-59.62%	-65.83%	-59.69%	-56.32%
Return on Assets (ROA)	-10.00%	-22.20%	-9.66%	1.92%	-6.60%	-9.30%	-81.30%	-70.31%	-70.38%	-62.65%	-59.20%
Return on Common Equity (ROCE)	-33.30%	-59.08%	-21.67%	3.89%	-12.25%	-15.17%	-240.11%	416.44%	-290.04%	-122.70%	-93.50%
Return on Equity Simple (ROE_SIMPLE)	-36.50%	-70.98%	-21.50%	3.59%	-9.39%	-12.70%	-93.40%	250.56%	1,407.91%	-114.10%	-145.72%
Net Operating Profit after Tax (NOPAT)	-69	-163	-65	22	-5.57	-12	-31	-44	-55	-48	-53
NOPAT Margin	-7.38%	-21.83%	-8.11%	3.16%	-1.12%	-3.23%	-16.99%	-40.95%	-64.85%	-66.30%	-106.52%
Net Nonoperating Expense Percent (NNEP)	-15.36%	-22.98%	-8.76%	-2.12%	-12.57%	-8.54%	-238.36%	76.46%	-282.34%	-57.64%	-37.41%
Return On Investment Capital (ROIC_SIMPLE)	-11.34%	-27.27%	-8.99%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	47.93%	50.83%	48.46%	46.47%	47.77%	46.40%	51.15%	59.02%	72.00%	63.51%	69.33%
SG&A Expenses to Revenue	41.46%	47.14%	41.90%	37.21%	41.08%	45.74%	57.23%	80.28%	98.32%	107.92%	151.08%
R&D to Revenue	21.15%	33.22%	21.24%	13.10%	12.74%	12.48%	15.90%	19.20%	22.33%	23.28%	31.76%
Operating Expenses to Revenue	62.61%	80.37%	63.13%	50.31%	53.82%	58.22%	73.13%	99.48%	120.65%	131.21%	182.84%
Earnings before Interest and Taxes (EBIT)	-99	-233	-93	21	-25	-28	-111	-62	-78	-69	-76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-83	-212	-72	37	-5.79	-22	-103	-53	-72	-64	-71
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.99	6.15	6.57	22.08	16.25	18.07	16.59	0.00	0.00	5.60	5.47
Price to Tangible Book Value (P/TBV)	8.99	6.15	6.57	22.08	16.25	18.07	16.59	0.00	0.00	5.79	5.73
Price to Revenue (P/Rev)	2.52	2.58	3.61	13.61	11.93	9.72	11.85	0.22	0.78	4.88	6.00
Price to Earnings (P/E)	0.00	0.00	0.00	649.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	22.20	13.35	24.06	101.58	67.20	180.66	911.60	3.72	5.10	15.86	17.56
Enterprise Value to Revenue (EV/Rev)	2.34	2.34	3.19	13.12	11.36	9.24	11.15	0.80	1.06	4.27	5.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	247.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	433.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	415.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	90.89	0.00	50.66	82.80	229.80	79.85	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	585.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.33	0.91	0.64	0.65	0.55	0.00	0.00	-2.63	-13.32	0.46	0.54
Long-Term Debt to Equity	1.17	0.91	0.64	0.65	0.55	0.00	0.00	-2.63	-13.32	0.46	0.54
Financial Leverage	-0.60	-0.69	-0.77	-0.78	-0.82	-0.94	-0.75	-2.16	-0.35	-0.71	-0.83
Leverage Ratio	3.33	2.66	2.24	2.03	1.86	1.63	2.95	-5.92	4.12	1.96	1.58
Compound Leverage Factor	3.09	2.51	2.25	1.52	2.69	1.44	3.26	-6.98	4.41	2.06	1.66
Debt to Total Capital	57.01%	47.61%	39.16%	39.39%	35.66%	0.00%	0.00%	161.50%	108.12%	31.57%	35.04%
Short-Term Debt to Total Capital	6.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	50.37%	47.61%	39.16%	39.39%	35.66%	0.00%	0.00%	161.50%	108.12%	31.57%	35.04%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	42.99%	52.39%	60.84%	60.61%	64.34%	100.00%	100.00%	-61.50%	-8.12%	68.43%	64.96%
Debt to EBITDA	-4.22	-1.35	-3.92	7.57	-35.04	0.00	0.00	-1.44	-1.09	-0.46	-0.41
Net Debt to EBITDA	1.98	0.86	4.62	-9.20	48.67	0.00	0.00	-1.17	-0.32	0.68	0.56
Long-Term Debt to EBITDA	-3.73	-1.35	-3.92	7.57	-35.04	0.00	0.00	-1.44	-1.09	-0.46	-0.41
Debt to NOPAT	-5.03	-1.75	-4.36	12.69	-36.44	0.00	0.00	-1.74	-1.45	-0.61	-0.56
Net Debt to NOPAT	2.36	1.12	5.13	-15.44	50.62	0.00	0.00	-1.42	-0.43	0.91	0.75
Long-Term Debt to NOPAT	-4.44	-1.75	-4.36	12.69	-36.44	0.00	0.00	-1.74	-1.45	-0.61	-0.56
Altman Z-Score	1.72	1.09	3.11	12.93	10.38	14.92	13.17	-7.56	-5.60	-0.59	-0.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.93	3.83	5.14	6.15	6.14	2.78	2.83	1.78	2.93	4.03	5.02
Quick Ratio	2.24	2.94	4.43	5.57	5.46	2.24	2.48	0.97	2.06	3.21	4.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-188	-81	16	-71	-28	-10	-50	-52	-53	-54
Operating Cash Flow to CapEx	125.97%	-118.68%	148.00%	785.32%	90.01%	214.45%	-278.60%	-1,156.63%	-685.03%	-1,019.50%	-1,393.05%
Free Cash Flow to Firm to Interest Expense	-4.35	-19.00	-12.97	2.61	-5.58	0.00	-0.80	-4.39	-9.20	-14.22	-13.92
Operating Cash Flow to Interest Expense	2.79	-3.22	8.13	18.44	1.93	0.00	-0.65	-5.83	-10.72	-15.71	-15.73
Operating Cash Flow Less CapEx to Interest Expense	0.58	-5.93	2.64	16.09	-0.21	0.00	-0.88	-6.34	-12.28	-17.25	-16.86
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.98	0.75	0.82	0.87	0.96	1.36	1.22	1.04	0.71	0.63	0.37
Accounts Receivable Turnover	8.54	6.79	7.11	7.29	7.75	8.86	6.57	6.73	6.68	6.71	7.68
Inventory Turnover	2.93	2.82	4.32	4.94	4.23	4.87	4.01	2.64	3.13	3.14	3.10
Fixed Asset Turnover	12.16	10.31	13.47	14.00	12.03	14.47	10.00	5.66	4.97	5.18	4.43
Accounts Payable Turnover	9.56	7.22	9.27	14.25	13.41	13.68	15.71	10.03	9.52	12.88	16.03
Days Sales Outstanding (DSO)	42.73	53.76	51.35	50.10	47.11	41.19	55.57	54.22	54.65	54.38	47.54
Days Inventory Outstanding (DIO)	124.55	129.21	84.46	73.92	86.38	74.88	90.99	138.48	116.55	116.18	117.75
Days Payable Outstanding (DPO)	38.20	50.58	39.37	25.61	27.22	26.67	23.24	36.39	38.35	28.33	22.77
Cash Conversion Cycle (CCC)	129.09	132.39	96.43	98.40	106.27	89.40	123.33	156.30	132.85	142.23	142.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	99	131	106	91	84	19	2.25	23	17	20	15
Invested Capital Turnover	8.18	6.31	8.13	8.03	9.70	34.89	14.44	5.29	4.54	4.24	3.53
Increase / (Decrease) in Invested Capital	-32	24	16	6.42	66	16	-21	5.72	-2.14	4.91	1.33
Enterprise Value (EV)	2,202	1,746	2,557	9,221	5,669	3,346	2,049	86	89	311	259
Market Capitalization	2,366	1,929	2,890	9,563	5,951	3,523	2,178	24	66	355	298
Book Value per Share	$4.01	$4.81	$6.84	$6.82	$5.89	$3.30	$2.29	($2.88)	($0.19)	$2.11	$2.32
Tangible Book Value per Share	$4.01	$4.81	$6.84	$6.82	$5.89	$3.30	$2.29	($3.02)	($0.25)	$2.04	$2.22
Total Capital	612	599	723	715	569	195	131	47	73	93	84
Total Debt	349	285	283	281	203	0.00	0.00	77	79	29	29
Total Long-Term Debt	308	285	283	281	203	0.00	0.00	77	79	29	29
Net Debt	-164	-183	-334	-342	-282	-176	-129	62	23	-44	-40
Capital Expenditures (CapEx)	19	27	34	14	27	20	2.99	5.72	8.93	5.76	4.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	80	85	68	56	48	0.29	-7.43	14	5.08	7.36	3.38
Debt-free Net Working Capital (DFNWC)	518	553	685	680	533	177	122	28	61	80	73
Net Working Capital (NWC)	477	553	685	680	533	177	122	28	61	80	73
Net Nonoperating Expense (NNE)	27	59	30	6.61	29	13	91	29	29	24	27
Net Nonoperating Obligations (NNO)	-164	-183	-334	-342	-282	-176	-129	52	23	-44	-40
Total Depreciation and Amortization (D&A)	16	22	20	16	19	5.51	8.08	8.73	5.68	4.97	4.56
Debt-free, Cash-free Net Working Capital to Revenue	8.49%	11.34%	8.46%	7.95%	9.71%	0.08%	-4.04%	12.91%	6.03%	10.10%	6.79%
Debt-free Net Working Capital to Revenue	55.11%	73.92%	85.46%	96.71%	106.93%	48.78%	66.13%	26.09%	71.95%	110.45%	146.13%
Net Working Capital to Revenue	50.78%	73.92%	85.46%	96.71%	106.93%	48.78%	66.13%	26.09%	71.95%	110.45%	146.13%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.47)	($3.43)	($1.47)	$0.25	($0.56)	($0.42)	($2.55)	($12.87)	($27.30)	($25.00)	($34.20)
Adjusted Weighted Average Basic Shares Outstanding	65.45M	64.97M	64.15M	63M	62.50M	59.73M	57.72M	44.70M	3.13M	3.03M	2.37M
Adjusted Diluted Earnings per Share	($1.47)	($3.43)	($1.47)	$0.24	($0.56)	($0.42)	($2.55)	($12.87)	($27.30)	($25.00)	($34.20)
Adjusted Weighted Average Diluted Shares Outstanding	65.45M	64.97M	64.15M	64.35M	62.50M	59.73M	57.72M	44.70M	3.13M	3.03M	2.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.56)	($0.42)	($2.55)	($12.87)	($27.30)	($25.00)	($34.20)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.47M	65.63M	64.53M	63.87M	60.99M	58.51M	48.13M	5.68M	3.06M	2.89M	2.33M
Normalized Net Operating Profit after Tax (NOPAT)	-69	-163	-65	22	-5.57	-12	-31	-44	-55	-48	-53
Normalized NOPAT Margin	-7.38%	-21.83%	-8.11%	3.16%	-1.12%	-3.23%	-16.99%	-40.95%	-64.85%	-66.30%	-106.52%
Pre Tax Income Margin	-9.77%	-29.46%	-11.59%	2.26%	-7.27%	-6.79%	-66.66%	-67.87%	-99.07%	-99.39%	-159.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.42	-23.60	-14.93	3.52	-1.96	0.00	-8.63	-5.46	-13.68	-18.45	-19.40
NOPAT to Interest Expense	-7.99	-16.52	-10.47	3.67	-0.44	0.00	-2.43	-3.89	-9.57	-12.91	-13.58
EBIT Less CapEx to Interest Expense	-13.63	-26.31	-20.42	1.17	-4.10	0.00	-8.86	-5.96	-15.24	-19.99	-20.53
NOPAT Less CapEx to Interest Expense	-10.21	-19.23	-15.96	1.32	-2.58	0.00	-2.66	-4.39	-11.14	-14.45	-14.71
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-31.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Tandem Diabetes Care's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.30%	43.62%	31.43%	13.27%	13.16%	-10.75%	-9.25%	-2.17%	-3.71%	5.00%	13.87%
EBITDA Growth	-213.24%	108.10%	12.11%	21.92%	69.73%	-134.81%	39.39%	-366.23%	-1,054.12%	-174.99%	-468.10%
EBIT Growth	-190.03%	98.34%	17.28%	20.70%	67.39%	-97.21%	33.58%	-217.08%	-733.34%	-239.92%	-748.10%
NOPAT Growth	-190.03%	-11.90%	17.28%	20.70%	67.39%	-97.21%	33.58%	-217.08%	-733.34%	-200.74%	-534.65%
Net Income Growth	-205.64%	102.52%	29.46%	13.87%	65.52%	-89.25%	32.69%	-137.61%	-741.81%	-246.68%	-945.18%
EPS Growth	-203.08%	0.00%	31.37%	14.55%	66.15%	-87.50%	32.89%	-129.17%	-734.78%	-241.18%	-944.44%
Operating Cash Flow Growth	-128.59%	248.52%	48,589.09%	16.57%	56.37%	-223.99%	-99.77%	-191.62%	-232.80%	-70.36%	-29.88%
Free Cash Flow Firm Growth	45.06%	108.43%	-15.25%	-22.17%	54.73%	-75.35%	50.18%	-54.24%	-648.36%	-570.79%	-674.15%
Invested Capital Growth	-46.96%	-24.16%	12.36%	21.93%	19.36%	23.03%	4.74%	9.85%	22.59%	17.09%	26.67%
Revenue Q/Q Growth	-17.06%	15.85%	9.94%	15.77%	-2.60%	6.02%	-5.25%	15.67%	-23.18%	7.80%	2.14%
EBITDA Q/Q Growth	-4,905.66%	110.93%	12.28%	31.99%	-24.21%	-18.62%	22.08%	73.63%	-863.41%	69.38%	-499.40%
EBIT Q/Q Growth	-20,669.42%	97.77%	15.21%	26.16%	-18.88%	-11.14%	18.72%	69.64%	-618.96%	62.57%	-288.05%
NOPAT Q/Q Growth	-208.10%	-50.36%	15.21%	26.16%	-18.88%	-11.14%	18.72%	69.64%	-618.96%	62.57%	-288.05%
Net Income Q/Q Growth	-17,392.19%	103.25%	24.54%	27.86%	-42.37%	8.98%	7.87%	71.12%	-681.39%	67.63%	-225.25%
EPS Q/Q Growth	0.00%	0.00%	25.53%	27.69%	-44.44%	11.76%	7.27%	71.35%	-700.00%	68.42%	-216.67%
Operating Cash Flow Q/Q Growth	-270.55%	-59.98%	607.66%	34.03%	-10.81%	-13,220.00%	100.87%	65.50%	-414.88%	-75.69%	246.95%
Free Cash Flow Firm Q/Q Growth	-752.65%	113.47%	31.54%	8.69%	-0.13%	-84.13%	27.43%	66.17%	-287.84%	47.68%	-124.67%
Invested Capital Q/Q Growth	-34.35%	-12.12%	-12.79%	5.41%	-6.12%	30.21%	-5.37%	3.18%	-3.23%	10.84%	-0.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	50.51%	55.71%	51.09%	50.83%	49.39%	47.41%	48.35%	51.93%	48.95%	52.39%	51.05%
EBITDA Margin	-50.00%	0.86%	-9.15%	-11.47%	-19.52%	-15.31%	-13.68%	-16.64%	-72.97%	-5.82%	-20.49%
Operating Margin	-51.56%	-0.21%	-10.70%	-13.87%	-21.74%	-17.82%	-16.99%	-19.81%	-75.46%	-8.06%	-23.22%
EBIT Margin	-51.56%	-0.21%	-10.70%	-13.87%	-21.74%	-17.82%	-16.99%	-19.81%	-75.46%	-8.06%	-23.22%
Profit (Net Income) Margin	-55.69%	0.27%	-9.53%	-13.89%	-22.29%	-15.25%	-17.76%	-18.26%	-73.13%	-7.19%	-23.94%
Tax Burden Percent	106.94%	4,718.75%	102.82%	103.60%	108.06%	95.82%	107.26%	103.31%	100.23%	98.38%	103.42%
Interest Burden Percent	101.00%	-2.75%	86.67%	96.65%	94.84%	89.30%	97.41%	89.23%	96.69%	90.64%	99.70%
Effective Tax Rate	0.00%	-4,618.75%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-377.74%	-79.47%	-59.98%	-65.62%	-103.91%	-78.68%	-93.50%	-108.12%	-449.58%	-45.90%	-149.81%
ROIC Less NNEP Spread (ROIC-NNEP)	-334.09%	-95.74%	-57.04%	-59.96%	-96.30%	-76.56%	-89.46%	-105.13%	-437.91%	-44.89%	-144.89%
Return on Net Nonoperating Assets (RNNOA)	176.54%	57.57%	34.99%	34.88%	58.96%	52.48%	65.60%	77.77%	332.55%	34.76%	114.26%
Return on Equity (ROE)	-201.20%	-21.89%	-24.99%	-30.74%	-44.94%	-26.20%	-27.90%	-30.35%	-117.04%	-11.14%	-35.55%
Cash Return on Invested Capital (CROIC)	-71.52%	-32.88%	-99.35%	-102.43%	-108.93%	-158.41%	-158.64%	-169.54%	-174.23%	-81.71%	-74.39%
Operating Return on Assets (OROA)	-54.41%	-0.20%	-9.63%	-11.72%	-17.67%	-13.28%	-13.19%	-15.79%	-60.90%	-6.60%	-19.35%
Return on Assets (ROA)	-58.76%	0.26%	-8.58%	-11.73%	-18.11%	-11.37%	-13.78%	-14.55%	-59.02%	-5.88%	-19.95%
Return on Common Equity (ROCE)	-201.20%	-21.89%	-24.99%	-30.74%	-44.94%	-26.20%	-27.90%	-30.35%	-117.04%	-11.14%	-35.55%
Return on Equity Simple (ROE_SIMPLE)	-118.40%	0.00%	-53.33%	-58.36%	-58.20%	0.00%	-66.39%	-68.18%	-60.15%	0.00%	-16.10%
Net Operating Profit after Tax (NOPAT)	-85	-27	-18	-22	-29	-25	-22	-27	-89	-12	-33
NOPAT Margin	-36.10%	-9.72%	-7.49%	-9.71%	-15.22%	-12.47%	-11.90%	-13.87%	-52.82%	-5.64%	-16.25%
Net Nonoperating Expense Percent (NNEP)	-43.65%	16.27%	-2.95%	-5.66%	-7.60%	-2.11%	-4.03%	-2.99%	-11.67%	-1.01%	-4.91%
Return On Investment Capital (ROIC_SIMPLE)	-16.76%	-4.49%	-	-	-	-4.10%	-	-	-	-1.72%	-
Cost of Revenue to Revenue	49.49%	44.29%	48.91%	49.17%	50.61%	52.59%	51.65%	48.07%	51.05%	47.61%	48.95%
SG&A Expenses to Revenue	48.57%	37.44%	40.84%	42.47%	47.01%	43.57%	42.74%	49.82%	53.02%	44.30%	41.12%
R&D to Revenue	53.51%	18.47%	20.95%	22.23%	24.13%	21.65%	22.61%	21.91%	71.38%	16.15%	33.15%
Operating Expenses to Revenue	102.07%	55.91%	61.79%	64.70%	71.14%	65.22%	65.35%	71.74%	124.41%	60.45%	74.27%
Earnings before Interest and Taxes (EBIT)	-121	-0.58	-26	-31	-42	-35	-32	-39	-128	-18	-47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-117	2.44	-22	-25	-37	-30	-25	-33	-124	-13	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.20	8.99	11.68	11.13	9.50	6.15	4.30	4.82	7.74	6.57	7.29
Price to Tangible Book Value (P/TBV)	8.20	8.99	11.68	11.13	9.50	6.15	4.30	4.82	7.74	6.57	7.29
Price to Revenue (P/Rev)	1.30	2.52	3.25	3.27	3.00	2.58	1.75	2.01	3.30	3.61	3.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	18.18	22.20	23.50	19.30	17.83	13.35	11.33	12.84	23.19	24.06	28.65
Enterprise Value to Revenue (EV/Rev)	1.20	2.34	3.10	3.14	2.84	2.34	1.48	1.72	3.00	3.19	3.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	84.88	90.89	421.41	0.00	0.00	0.00	0.00	266.47	130.03	50.66	42.74
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.25	1.33	1.47	1.49	1.43	0.91	0.91	0.86	0.84	0.64	0.67
Long-Term Debt to Equity	1.99	1.17	1.30	1.31	1.43	0.91	0.91	0.86	0.84	0.64	0.67
Financial Leverage	-0.53	-0.60	-0.61	-0.58	-0.61	-0.69	-0.73	-0.74	-0.76	-0.77	-0.79
Leverage Ratio	4.68	3.33	3.44	3.35	3.26	2.66	2.70	2.55	2.54	2.24	2.34
Compound Leverage Factor	4.72	-0.09	2.98	3.23	3.09	2.38	2.63	2.27	2.45	2.03	2.33
Debt to Total Capital	69.23%	57.01%	59.45%	59.80%	58.84%	47.61%	47.54%	46.32%	45.58%	39.16%	40.13%
Short-Term Debt to Total Capital	8.07%	6.65%	6.93%	6.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	61.16%	50.37%	52.52%	52.83%	58.84%	47.61%	47.54%	46.32%	45.58%	39.16%	40.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	30.77%	42.99%	40.55%	40.20%	41.16%	52.39%	52.46%	53.68%	54.42%	60.84%	59.87%
Debt to EBITDA	-2.15	-4.22	-3.02	-2.94	-2.77	-1.35	-1.46	-1.35	-1.53	-3.92	-6.66
Net Debt to EBITDA	0.55	1.98	1.08	0.88	0.96	0.86	1.10	1.06	1.27	4.62	7.68
Long-Term Debt to EBITDA	-1.90	-3.73	-2.67	-2.60	-2.77	-1.35	-1.46	-1.35	-1.53	-3.92	-6.66
Debt to NOPAT	-2.80	-5.03	-3.73	-3.57	-3.37	-1.75	-1.88	-1.75	-1.97	-4.36	-6.48
Net Debt to NOPAT	0.72	2.36	1.34	1.07	1.17	1.12	1.41	1.37	1.64	5.13	7.47
Long-Term Debt to NOPAT	-2.47	-4.44	-3.29	-3.16	-3.37	-1.75	-1.88	-1.75	-1.97	-4.36	-6.48
Altman Z-Score	0.33	2.06	2.20	2.06	1.87	1.77	1.36	1.67	2.43	3.35	3.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.30	2.93	2.90	3.05	3.81	3.83	4.05	4.38	4.43	5.14	4.81
Quick Ratio	1.72	2.24	2.24	2.29	2.91	2.94	3.20	3.47	3.57	4.43	4.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	4.13	-31	-45	-49	-49	-27	-37	-108	-28	-53
Operating Cash Flow to CapEx	-616.46%	349.20%	511.15%	-81.58%	-179.40%	-138.80%	1.02%	-85.71%	-207.59%	103.43%	174.64%
Free Cash Flow to Firm to Interest Expense	-14.48	2.22	-16.45	-25.00	-15.51	-27.19	-5.50	-22.86	-66.35	-17.70	-33.90
Operating Cash Flow to Interest Expense	-9.82	5.76	14.36	-2.94	-2.53	-4.00	0.01	-3.94	-11.22	3.69	15.19
Operating Cash Flow Less CapEx to Interest Expense	-11.41	4.11	11.55	-6.55	-3.93	-6.89	-1.10	-8.54	-16.62	0.12	6.49
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.06	0.98	0.90	0.84	0.81	0.75	0.78	0.80	0.81	0.82	0.83
Accounts Receivable Turnover	8.96	8.54	8.23	8.09	8.35	6.79	7.24	7.81	8.57	7.11	7.90
Inventory Turnover	3.18	2.93	2.90	2.62	2.74	2.82	3.07	3.27	3.69	4.32	4.45
Fixed Asset Turnover	12.54	12.16	10.90	10.45	10.12	10.31	10.38	11.92	12.76	13.47	12.91
Accounts Payable Turnover	8.70	9.56	9.04	7.73	7.56	7.22	7.09	7.16	7.75	9.27	8.58
Days Sales Outstanding (DSO)	40.76	42.73	44.33	45.13	43.69	53.76	50.42	46.75	42.61	51.35	46.22
Days Inventory Outstanding (DIO)	114.66	124.55	125.91	139.19	133.39	129.21	118.76	111.51	99.02	84.46	81.99
Days Payable Outstanding (DPO)	41.95	38.20	40.38	47.19	48.31	50.58	51.51	50.97	47.08	39.37	42.56
Cash Conversion Cycle (CCC)	113.47	129.09	129.86	137.12	128.78	132.39	117.67	107.29	94.55	96.43	85.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	65	99	113	129	123	131	100	106	103	106	96
Invested Capital Turnover	10.47	8.18	8.01	6.76	6.83	6.31	7.86	7.80	8.51	8.13	9.22
Increase / (Decrease) in Invested Capital	-58	-32	12	23	20	24	4.54	9.52	19	16	20
Enterprise Value (EV)	1,183	2,202	2,651	2,498	2,189	1,746	1,138	1,363	2,385	2,557	2,747
Market Capitalization	1,274	2,366	2,776	2,602	2,309	1,929	1,352	1,586	2,620	2,890	3,073
Book Value per Share	$2.34	$4.01	$3.63	$3.62	$3.72	$4.81	$4.83	$5.09	$5.25	$6.84	$6.57
Tangible Book Value per Share	$2.34	$4.01	$3.63	$3.62	$3.72	$4.81	$4.83	$5.09	$5.25	$6.84	$6.57
Total Capital	505	612	586	582	591	599	599	613	622	723	705
Total Debt	349	349	348	348	347	285	285	284	284	283	283
Total Long-Term Debt	309	308	308	307	347	285	285	284	284	283	283
Net Debt	-90	-164	-125	-104	-120	-183	-214	-223	-236	-334	-326
Capital Expenditures (CapEx)	2.97	3.07	5.24	6.47	4.46	5.20	5.40	7.38	8.83	5.63	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	47	80	61	81	74	85	73	82	67	68	52
Debt-free Net Working Capital (DFNWC)	416	518	534	533	542	553	571	590	587	685	661
Net Working Capital (NWC)	375	477	494	493	542	553	571	590	587	685	661
Net Nonoperating Expense (NNE)	46	-28	4.99	9.27	14	5.46	11	8.61	34	3.41	16
Net Nonoperating Obligations (NNO)	-90	-164	-125	-104	-120	-183	-214	-223	-236	-334	-326
Total Depreciation and Amortization (D&A)	3.67	3.02	3.77	5.33	4.26	4.93	6.15	6.21	4.21	4.95	5.59
Debt-free, Cash-free Net Working Capital to Revenue	4.82%	8.49%	7.12%	10.16%	9.66%	11.34%	9.45%	10.43%	8.45%	8.46%	6.57%
Debt-free Net Working Capital to Revenue	42.32%	55.11%	62.52%	67.00%	70.42%	73.92%	74.02%	74.61%	73.84%	85.46%	83.55%
Net Working Capital to Revenue	38.18%	50.78%	57.77%	61.91%	70.42%	73.92%	74.02%	74.61%	73.84%	85.46%	83.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.97)	$0.00	($0.35)	($0.47)	($0.65)	($0.45)	($0.51)	($0.55)	($1.92)	($0.25)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	66.40M	65.45M	65.54M	64.99M	65.33M	64.97M	65.12M	64.83M	64.55M	64.15M	64.24M
Adjusted Diluted Earnings per Share	($1.97)	$0.00	($0.35)	($0.47)	($0.65)	($0.45)	($0.51)	($0.55)	($1.92)	($0.24)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	66.40M	65.45M	65.54M	64.99M	65.33M	64.97M	65.12M	64.83M	64.55M	64.15M	64.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.61M	66.47M	65.68M	65.46M	64.59M	65.63M	65.21M	65.08M	64.62M	64.53M	64.30M
Normalized Net Operating Profit after Tax (NOPAT)	-85	-0.41	-18	-22	-29	-25	-22	-27	-89	-12	-33
Normalized NOPAT Margin	-36.10%	-0.14%	-7.49%	-9.71%	-15.22%	-12.47%	-11.90%	-13.87%	-52.82%	-5.64%	-16.25%
Pre Tax Income Margin	-52.08%	0.01%	-9.27%	-13.40%	-20.62%	-15.91%	-16.55%	-17.68%	-72.96%	-7.31%	-23.15%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-64.92	-0.31	-13.99	-17.16	-13.17	-19.45	-6.52	-24.18	-78.22	-11.26	-30.14
NOPAT to Interest Expense	-45.44	-14.77	-9.79	-12.01	-9.22	-13.61	-4.56	-16.93	-54.76	-7.88	-21.09
EBIT Less CapEx to Interest Expense	-66.51	-1.96	-16.80	-20.77	-14.58	-22.33	-7.63	-28.78	-83.63	-14.82	-38.83
NOPAT Less CapEx to Interest Expense	-47.04	-16.42	-12.60	-15.62	-10.63	-16.50	-5.68	-21.52	-60.16	-11.45	-29.79
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-31.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Tandem Diabetes Care's Financials

When does Tandem Diabetes Care's financial year end?

According to the most recent income statement we have on file, Tandem Diabetes Care's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Tandem Diabetes Care's net income changed over the last 10 years?

Tandem Diabetes Care's net income appears to be on an upward trend, with a most recent value of -$96.03 million in 2024, rising from -$79.52 million in 2014. The previous period was -$222.61 million in 2023. Find out what analysts predict for Tandem Diabetes Care in the coming months.

What is Tandem Diabetes Care's operating income?

Tandem Diabetes Care's total operating income in 2024 was -$99.13 million, based on the following breakdown:

Total Gross Profit: $489.57 million
Total Operating Expenses: $588.70 million

How has Tandem Diabetes Care revenue changed over the last 10 years?

Over the last 10 years, Tandem Diabetes Care's total revenue changed from $49.72 million in 2014 to $940.20 million in 2024, a change of 1,790.9%.

How much debt does Tandem Diabetes Care have?

Tandem Diabetes Care's total liabilities were at $704.56 million at the end of 2024, a 10.3% increase from 2023, and a 1,257.7% increase since 2014.

How much cash does Tandem Diabetes Care have?

In the past 10 years, Tandem Diabetes Care's cash and equivalents has ranged from $13.70 million in 2017 to $172.52 million in 2022, and is currently $69.23 million as of their latest financial filing in 2024.

How has Tandem Diabetes Care's book value per share changed over the last 10 years?

Over the last 10 years, Tandem Diabetes Care's book value per share changed from 2.32 in 2014 to 4.01 in 2024, a change of 72.5%.

Related Companies

This page (NASDAQ:TNDM) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Financials

Frequently Asked Questions About Tandem Diabetes Care's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Financials

Annual Income Statements for Tandem Diabetes Care

Quarterly Income Statements for Tandem Diabetes Care

Annual Cash Flow Statements for Tandem Diabetes Care

Quarterly Cash Flow Statements for Tandem Diabetes Care

Annual Balance Sheets for Tandem Diabetes Care

Quarterly Balance Sheets for Tandem Diabetes Care

Annual Metrics And Ratios for Tandem Diabetes Care

Quarterly Metrics And Ratios for Tandem Diabetes Care

Frequently Asked Questions About Tandem Diabetes Care's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools